WebDisclosure WebDisclosure
Basculer en Français
11289 Companies
250811 Keywords
179538 Articles
136599 Press releases
Headlines Articles Press releases CAGE Bio Inc. Remove
  1. Home
  2. Companies
  3. CAGE Bio Inc.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 01/09/2025 at 21:05, 1 year 9 months ago

    CAGE Bio Launches Phase 2b Trial for Atopic Dermatitis Treatment CGB-500

    Phase 2B Trial Atopic Dermatitis CAGE Bio CGB-500 Ionic Liquid Technology
  • BRIEF

    published on 01/09/2025 at 21:05, 1 year 9 months ago

    CAGE Bio lance un essai de phase 2b pour le traitement de la dermatite atopique CGB-500

    CGB-500 Biographie De CAGE Essai De Phase 2b Dermatite Atopique Technologie Des Liquides Ioniques
  • PRESS RELEASE

    published on 01/09/2025 at 21:00, 1 year 9 months ago

    CAGE Bio Announces Phase 2b Trial for CGB-500 (1% Tofacitinib), a Breakthrough Topical JAK Inhibitor for Moderate to Severe Atopic Dermatitis

    CAGE Bio initiates Phase 2b trial for CGB-500, a topical JAK inhibitor ointment for atopic dermatitis. High efficacy, low side-effects. Improving patient outcomes
    Phase 2B Trial Atopic Dermatitis CAGE Bio CGB-500 Topical Therapy
    Logo of CAGE Bio Inc.
  • PRESS RELEASE

    published on 08/03/2023 at 16:45, 3 years 3 months ago

    CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

    Logo of CAGE Bio Inc.
Accesswire
  • Published on 11/05/2026 at 15:20, 10 minutes ago

    MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors

  • Published on 11/05/2026 at 14:31, 59 minutes ago

    First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile

  • Published on 11/05/2026 at 14:25, 1 hour 5 minutes ago

    Polaris Renewable Energy Announces Q3 2026 Results

  • Published on 11/05/2026 at 14:20, 1 hour 10 minutes ago

    Polaris Renewable Energy Declares Quarterly Dividend

  • Published on 11/05/2026 at 14:15, 1 hour 15 minutes ago

    Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook

View all ACCESSWIRE
EQS Group
  • Published on 11/05/2026 at 15:10, 20 minutes ago

    Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer

  • Published on 11/05/2026 at 14:58, 31 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.

  • Published on 11/05/2026 at 14:58, 32 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.

  • Published on 11/05/2026 at 14:57, 33 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: DCC plc

  • Published on 11/05/2026 at 14:57, 33 minutes ago

    Form 8.3 - The Vanguard Group, Inc.: Rotork plc

View all EQS
Les Echos
  • Published on 11/05/2026 at 15:01, 29 minutes ago

    Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027

  • Published on 11/05/2026 at 10:16, 5 hours 14 minutes ago

    Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %

  • Published on 11/05/2026 at 10:16, 5 hours 14 minutes ago

    Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

  • Published on 11/05/2026 at 07:44, 7 hours 45 minutes ago

    Résultats d’ENGIE 9 mois 2026

  • Published on 11/05/2026 at 07:44, 7 hours 45 minutes ago

    ENGIE 9M 2026 results

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy